Lazarus syndrome in nonsmall cell lung cancer patients with poor performance status and major leukocytosis following nivolumab treatment

Johan Pluvy, Solenn Brosseau, Charles Naltet, Marie-Agnès Opsomer, Aurélie Cazes, Claire Danel, Antoine Khalil, Gérard Zalcman, Valerie Gounant

Source: Eur Respir J, 50 (1) 1700310; 10.1183/13993003.00310-2017
Journal Issue: July

Congress or journal article abstractFull text journal articlePDF journal article, handout or slides

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
Johan Pluvy, Solenn Brosseau, Charles Naltet, Marie-Agnès Opsomer, Aurélie Cazes, Claire Danel, Antoine Khalil, Gérard Zalcman, Valerie Gounant. Lazarus syndrome in nonsmall cell lung cancer patients with poor performance status and major leukocytosis following nivolumab treatment. Eur Respir J, 50 (1) 1700310; 10.1183/13993003.00310-2017

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
Chemotherapy improves low performance status lung cancer patients
Source: Eur Respir J 2007; 30: 1186-1192
Year: 2007



Should patients with metastatic NSCLC and poor performance status be treated by chemotherapy?
Source: Annual Congress 2007 - Treatment of metastatic nonsmall cell lung cancer in the era of targeted therapies
Year: 2007


Effect of physical characteristics on patient response to nivolumab in non-small-cell lung cancer
Source: International Congress 2017 – Lung cancer - clinical research: scientific pearls from the bedside
Year: 2017


Symptoms, signs and staging of lung cancer
Source: ISSN=1025-448x, ISBN=1-904097-18-9, page=86
Year: 2001

Efficacy of next treatment received after nivolumab progression in patients with advanced nonsmall cell lung cancer
Source: ERJ Open Res, 4 (2) 00120-2017; 10.1183/23120541.00120-2017
Year: 2018



Clonality of multifocal nonsmall cell lung cancer: implications for staging and therapy
Source: Eur Respir J 2012; 39: 1437-1442
Year: 2012



Assessment of lung cancer related symptoms and chemotherapy related side effects in a group of patients with advanced lung cancer receiving palliative chemotherapy
Source: Eur Respir J 2006; 28: Suppl. 50, 752s
Year: 2006

The prognostic value of anemia, thrombocytosis and leukocytosis at time of diagnosis in patients with non-small cell lung cancer
Source: Annual Congress 2011 - Instructive clinical aspects of lung cancer
Year: 2011


A variant in LKB1 gene can predicts the clinical outcomes of chemotherapy in patients with non-small cell lung cancer
Source: International Congress 2018 – Lung cancer: new aspects in diagnosis and management
Year: 2018



Epidemiological and clinical predictors of survival during the first year of the treatment in non-small cell lung cancer patients
Source: Annual Congress 2009 - Treatment of lung cancer
Year: 2009

Second-line therapy in elderly patients with advanced nonsmall cell lung cancer
Source: Eur Respir J 2014; 43: 240-249
Year: 2004



Characteristics, incidence, risk factors, and practical management of pneumonitis associated with anti-PD-1 immunotherapy in patients with non-small cell lung cancer
Source: International Congress 2019 – Treatment of lung cancer
Year: 2019

The method of individualisation of treatment and prognosis for advanced non-small cell lung cancer
Source: Annual Congress 2010 - Prognostic factors for lung cancer
Year: 2010

Impact of radiotherapy on outcomes of nivolumab in advanced non-small cell lung cancer: a case controlled study
Source: International Congress 2018 – Lung cancer: personalised medicine
Year: 2018




The correlation between clinical and pathomorphological impacts of induction chemotherapy and long-term results of multimodality treatment for IIIA stage non-small cell lung cancer
Source: Annual Congress 2010 - Treatment of lung cancer
Year: 2010

Neo-adjuvant chemotherapy: level of evidence in early stage and in marginally resectable disease
Source: Annual Congress 2005 - Multidisciplinary treatment of non-metastatic non-small cell lung cancer: contemporary concepts
Year: 2005

Significance of febrile episode in patients with lung cancer during therapy - comparison of NSCLC and SCLC patients
Source: Eur Respir J 2002; 20: Suppl. 38, 356s
Year: 2002

Effect of comorbidity on the prognosis of non-small cell lung cancer
Source: Eur Respir J 2006; 28: Suppl. 50, 385s
Year: 2006

Systematic review of the effect of chemotherapy on quality of life (QoL) and symptom control in patients with non-small cell lung cancer (NSCLC)
Source: Annual Congress 2006 - Lung cancer treatment
Year: 2006


Survival and postoperative complication after neoadjuvant therapy in resectable stage IIIA-N2 non-small cell lung cancer: a balancing exercise
Source: Eur Respir J 2003; 22: Suppl. 45, 31s
Year: 2003